IP Library Granted Patent US 11,925,621
Granted Patent B2
US 11,925,621 · App. 17/260,123 · Granted Mar 12, 2024

Medicinal preparation for external use

Inventors: Masayasu Tanaka (Suita, JP); Yoshihiro Oyamada (Suita, JP); Yoshinori Takada (Osaka, JP)
Assignee: SUMITOMO PHARMA CO., LTD.
A61K31/4184A61K9/0014A61K9/06A61P29/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,925,621
App. No.
17/260,123
Granted
Mar 12, 2024
Kind
B2
Abstract

The present invention pertains to a drug for the treatment and/or prevention of pain, more specifically to a medicinal preparation for external use to treat and/or prevent peripheral neuropathic pain, the medicinal preparation containing as an active ingredient N 2 -{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alaninamide.

Claims (13)

1. A pharmaceutical composition for external use comprising N 2 -{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alaninamide or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the composition is substantially free from water.

2. The composition according to claim 1 , further comprising an external base comprising at least one selected from the group consisting of white petrolatum, yellow petrolatum, a gelled hydrocarbon, a paraffin, lanolin, hydrous lanolin, a lanolin alcohol, polyethylene glycol, silicon, a wax, a vegetable oil, lard, squalane, and a simple ointment.

3. The composition according to claim 1 , wherein the composition comprises the active ingredient in an amount of 0.01% (w/v)-10% (w/v).

4. The composition according to claim 1 , wherein the composition comprises an amount of water of 5% or less based on a total mass of the composition.

5. The composition according to claim 1 , wherein the composition is in a dosage form of an embrocation, a patch or a spray.

6. The composition according to claim 5 , wherein the embrocation is an ointment.

7. The composition according to claim 1 , for use in the treatment and/or prevention of pain.

8. The composition according to claim 7 , wherein the pain is peripheral neuropathic pain.

9. The composition according to claim 1 , wherein the composition comprises the active ingredient in an amount such that 0.1 mg or more of the active ingredient can be administered at a time in topical external administration.

10. A method of treating or preventing pain, comprising administering the composition according to claim 1 to a subject in need thereof.

11. The method according to claim 10 , wherein the pain is peripheral neuropathic pain.

12. The method according to claim 10 , wherein the composition comprises 0.1 mg or more of the active ingredient.

13. The method according to claim 10 , wherein the composition is in a dosage form of an ointment.

Assignments (2)
CHANGE OF NAME Recorded Jun 3, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 060096/0689 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2021
From: TANAKA, MASAYASU; OYAMADA, YOSHIHIRO; TAKADA, YOSHINORI
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 054908/0728 →
Priority Claims (1)
JP 2018-136147 · Jul 19, 2018 · national
Continuity (1)
Related Publication 20210322385A1 · Oct 21, 2021